01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of this division was primarily made possible through JAMP’s exclusive agreement with Alvotech. Through the creation of the BIOJAMP™ division, JAMP Pharma plans to establish itself as a Canadian leader in biosimilars.
01 Feb 22 | Lupin announced that it has entered into a license, supply and technology sharing agreement with Axantia Holding for biosimilar pegfilgrastim in certain territories, including Saudi Arabia, Jordan, Lebanon, Iraq, Sudan, Libya and Algeria.
02 Feb 22 | Alvotech announced that it has entered into an exclusive global licensing agreement with BiosanaPharma for the co-development of AVT23(BP001), a biosimilar omalizumab candidate.
02 Feb 22 | CA | Samsung Bioepis announced that Health Canada has approved Ontruzant® (biosimilar trastuzumab) for the treatment of adults with early breast cancer, metastatic breast cancer and metastatic gastric cancer.
02 Feb 22 | Bloomberg reported that the potential sale of Novartis’ Sandoz division has drawn a lot of interest from private equity as well as from other generics manufacturers. Bloomberg reported that Blackstone Inc and Carlyle Group Inc are in talks to potentially team up on an offer, with other companies such as Advent International, Hellman & Friedman and KKR & Co said to be considering offers. Novartis announced the potential sale of its Sandoz division in its Q3 2021 financial results and a decision on the future of Sandoz is expected by the end of 2022.
03 Feb 22 | Dr Reddy’s announced that it has entered into an agreement to acquire privately owned German medical cannabis company Nimbus Health GmbH. Dr Reddy’s said that the acquisition will allow it to introduce medical cannabis-based medicines as a promising treatment option for patients.
02 Feb 22 | AU | Australia’s National Medicines Policy Review Committee published a draft National Medicines Policy (NMP). The original NMP was established in 2000, with the stated aim of achieving both ‘optimal health outcomes and economic objectives’. The scope of the new NMP is proposed to be broadened to encompass biologic medicines, gene therapies, cell and tissue engineered products, and vaccines.
04 Feb 22 | CA | Nova Scotia launched a biosimilars switching program. The program applies to certain insulins and products used for arthritis, IBD and psoriasis and pharmacare beneficiaries will have 12 months to apply the switch to biosimilars. Similar programs have already been introduced in British Columbia, Quebec, Alberta and New Brunswick.
Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance. Call us today on 02 9023 9988 or email info@pearceIP.law.